PBM

Psyence Australia Pty Ltddistress 3/10 · well-funded / low risk

$2.91-1%today-99% from 52w high

psyencebiomed.com12 employeesToronto, ONBiotechnology

Lead: Adjustment Disorder

Revenue

pre-revenue

Liquidity

$16M

Runway

1.9 yrs

Shares 1y

Price & events

-38.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.4%

-3.3%

+0.0%

-67.8%

-36.6%

-99.1%

-100.0%

—

-100.0%

All

Overview

Market Cap: $6.67M
Volume: 6.96K
52 Week Range: $2.23 – $449
Total Shares: 2.29M
Float Shares: 2.61M
Short %: 1.35%
% Held by Insiders: 2.97%
% Held by Institutions: 4.02%
RVOL: 0.10x
Beta: 1.68

Pipeline stages · 1 programs

Psilocybin therapy

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-12-30

Pipeline · 1 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-12-30 Estimated 50% readout ~2027-02-13	Phase 2	Psilocybin therapy	Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia, Cancer of Endometrium, Cancer of Kidney, Cancer of Prostate, Cancer of the Breast, Cancer of Stomach, Cancer Melanoma Skin, Cancer Pancreas	—	recruiting

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 2,293,277 · 0 offerings/1y · 0 PIPEs

none

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — Adjustment Disorder

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.